remsima truxima herzuma yuflyma

Bio & Pharma Celltrion expands footprint in Latin America with flagship oncology drugs

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Bio & Pharma Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Bio & Pharma Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Bio & Pharma Celltrion establishes subsidiary in Vietnam

Celltrion Inc., South Korea’s largest biosimilar maker, said on Monday that it completed the establishment of a local subsidiary in Vietnam....

Bio & Pharma Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...

Bio & Pharma Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Bio & Pharma Celltrion's Remsima SC breaks 20% market share in Europe

South Korea's biopharmaceutical company Celltrion Inc. said on Wednesday that its subcutaneous autoimmune disease treatment Remsima SC has surpassed...

Bio & Pharma Celltrion to supply Remsima, Herzuma to Peru

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

Bio & Pharma Celltrion releases Remsima SC in Denmark

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Bio & Pharma Celltrion to deliver three treatments to Peru

South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...

Bio & Pharma Celltrion to supply Remsima SC, Yuflyma to Norway

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

Bio & Pharma Celltrion to export three anticancer drugs to Europe

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...

Bio & Pharma Celltrion to expand Yuflyma supply network in Europe

South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...

Bio & Pharma Celltrion applies for interchangeability of Yuflyma in US

South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...

Bio & Pharma Celltrion Healthcare's Herzuma selected as funded brand in NZ

Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...

Bio & Pharma Celltrion Healthcare's Remsima SC to be launched in US in 2024

Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...

Bio & Pharma Celltrion to supply Remsima to Brazil gov’t in three-year row

South Korea's Celltrion Healthcare Co. announced on Friday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for the B...

Bio & Pharma Celltrion gets FDA approval for Remsima SC

South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...

Bio & Pharma Celltrion Healthcare wins Remsima order in France, Italy

South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...

Bio & Pharma Celltrion Healthcare to supply Yuflyma to US pharmacy chain

South Korea's Celltrion Healthcare Co. has inked a deal with the US specialty pharmacy chain CarePartners Pharmacy to supply its autoimmune disease ...

Bio & Pharma Celltrion gets sales approval for Yuflyma in Japan

South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it has secured approval from the Japanese Ministry of Health, Labou...

Bio & Pharma Celltrion signs largest-ever quarterly deal with global sales affiliate

Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...

Bio & Pharma Celltrion Healthcare to supply Yuflyma to five regional gov’ts in Italy

South Korea's Celltrion Healthcare Co. announced on Monday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatm...

Bio & Pharma Celltrion Healthcare launches Humira biosimilar Yuflyma in US

South Korean biopharmaceutical company Celltrion Healthcare on Monday said it launched the day before on the US market Yuflyma, a biosimilar of the ...

Bio & Pharma Celltrion’s Remsima SC praised in Europe as preferred biosimilar

MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...

Bio & Pharma Celltrion Healthcare launches Remsima SC in Brazil

South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseas...

Bio & Pharma Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey

South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...

Bio & Pharma Celltrion's Truxima shows safety, efficacy in post-marketing study

South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...

Bio & Pharma Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...

Bio & Pharma Celltrion acquires approval to sell Vegzelma in Canada

South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...